Ticagrelor Sandoz 90 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ticagrelor sandoz 90 mg film-coat. tabl.

sandoz sa-nv - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor

Ticagrelor EG 60 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ticagrelor eg 60 mg film-coat. tabl.

eg sa-nv - ticagrelor 60 mg - film-coated tablet - 60 mg - ticagrelor 60 mg - ticagrelor

Ticagrelor EG 90 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ticagrelor eg 90 mg film-coat. tabl.

eg sa-nv - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor

Ticagrelor Mylan 60 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ticagrelor mylan 60 mg film-coat. tabl.

viatris gx bv-srl - ticagrelor 60 mg - film-coated tablet - 60 mg - ticagrelor 60 mg - ticagrelor

Ticagrelor Mylan 90 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ticagrelor mylan 90 mg film-coat. tabl.

viatris gx bv-srl - ticagrelor 90 mg - film-coated tablet - 90 mg - ticagrelor 90 mg - ticagrelor

TICAGRELOR INOVAMED 60 MG Israel - English - Ministry of Health

ticagrelor inovamed 60 mg

inovamed pharma ltd, israel - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor inovamed , co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event. limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

TICAGRELOR INOVAMED 90 MG Israel - English - Ministry of Health

ticagrelor inovamed 90 mg

inovamed pharma ltd, israel - ticagrelor - film coated tablets - ticagrelor 90 mg - ticagrelor - ticagrelor inovamed , co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event. limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

TICAGRELOR TEVA 60 MG Israel - English - Ministry of Health

ticagrelor teva 60 mg

teva israel ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor teva, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event . limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

TICAGRELOR TEVA 90 MG Israel - English - Ministry of Health

ticagrelor teva 90 mg

teva israel ltd - ticagrelor - film coated tablets - ticagrelor 90 mg - ticagrelor - ticagrelor teva, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event . limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

TICAGRELOR S.K. 60 MG Israel - English - Ministry of Health

ticagrelor s.k. 60 mg

k.s.kim international (sk- pharma) ltd., israel - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor s.k., co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event.limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.